The CAPItello-280 study (NCT05348577) was investigating Truqap in combination with docetaxel and androgen-deprivation therapy ...

AstraZeneca's hopes of developing its PD-L1 inhibitor Imfinzi for cervical cancer have been hit by a failed phase 3 trial of the drug alongside chemotherapy as a first-line treatment for women ...

The drug, a small molecule protein inhibitor, brought in $132 million in the first quarter, missing consensus estimates by 17 ...

A cancer drug from partners AstraZeneca and Daiichi Sankyo currently approved as a second-line or later treatment for metastatic breast cancer ... Enhertu’s label carries a black box warning ...

AstraZeneca ... drug cocktail when it was combined with another medicine, Pertuzumab. The trial was testing Enhertu’s effectiveness against HER2-positive metastatic breast cancer.

Also Read: European Drug Regulator Approves AstraZeneca’s Two Flagship Cancer Drugs For Breast And Lung Cancer Settings The PFS improvement was seen across all pre-specified patient subgroups ...

AstraZeneca’s immunotherapy combination including its checkpoint inhibitor drug Imfinzi has failed to improve overall survival in a first-line lung cancer trial – an indication where Merck ...

AstraZeneca (NASDAQ ... improvement as a first line treatment of metastatic breast cancer, compared to standard care. Enhertu, an antibody drug conjugate, is being jointly developed and ...

AstraZeneca (AZ) and Daiichi Sankyo’s Datroway (datopotamab deruxtecan) has been approved by the European Commission (EC) for use in certain cases of pre-treated breast cancer. The drug has been ...

AstraZeneca’s (AZ ... of a combination treatment for advanced breast cancer. The health technology assessment agency has recommended in final draft guidance that the drug be used in combination with ...

Daiichi Sankyo and ... to leverage Daiichi’s DXd ADC Technology and has secured approval in more than 75 nations for the treatment of HER2-positive breast cancer. Daiichi Sankyo research and ...